Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, OSU, Mayo Clinic, and More


Title: Methods for Diagnosing Pancreatic Cancer Using microRNAs

Patent Number: 8,507,202

Filed: Feb. 28, 2012

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent’s abstract states, “provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.”

Title: Folate Conjugates

Patent Number: 8,507,455

Filed: Dec. 4, 2008

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent’s abstract states, “provides iRNA agent[s] including at least one monomer” with a structure described in a pre-defined formula.

Title: Modified iRNA Agents

Patent Number: 8,507,661

Filed: Feb. 26, 2010

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

“The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose,” according to the patent’s abstract. “The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated. … The invention also relates to methods of making and using such modified iRNA agents.”

Title: Compositions and Methods for Inhibiting Expression of CD274/PD-L1 Gene

Patent Number: 8,507,663

Filed: April 6, 2011

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to double-stranded ribonucleic acid compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1,” the patent’s abstract states.

Title: Oral Delivery of Nucleic Acid-based Gene Interfering Agents by Salmonella

Application Number: 20130202557

Filed: Jan. 29, 2013

Lead Inventor: Hongjian Li, University of California, Oakland

The invention provides “vectors, including a novel attenuated strain of Salmonella, for efficient gene transfer into an animal,” the patent application’s abstract states.

Title: Compositions and Methods for Selectively Producing siRNA

Application Number: 20130202578

Filed: April 22, 2011

Lead Inventor: Noah Welker, University of Utah

The invention, the patent application’s abstract states, comprises “compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject [by] administering a Dicer enzyme comprising a helicase domain or a mutated Dicer enzyme to a subject. Also disclosed herein are methods of screening for a candidate modulator that modulates siRNA production.”

Title: Methods and Materials for Reducing Liver Fibrosis

Application Number: 20130202619

Filed: Oct. 23, 2012

Inventor: Michael Charlton, Mayo Clinic

The invention, the patent application’s abstract states, relates to “methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition. For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal are provided,” including ones incorporating siRNAs.

Title: Lipid Vectors Delivering Gene Silencers

Application Number: 20130202687

Filed: Oct. 14, 2011

Lead Inventor: Patrizia Perri, Giannina Gaslini Institute

The invention comprises a “lipid vector … [which] carries on its external surface at least one recognizing molecule directed against a cellular target molecule,” the patent application’s abstract states. “The recognizing molecule is directed against GD2 disialoganglioside epitope, a tumor-associated membrane antigen expressed abundantly by neuroectodermal tumor cells,” with the vector containing dsRNA against an oncogene.

Title: Preparation of Microvesicle-siRNA Complexes and Use Thereof in AIDS Treatment

Application Number: 20130203837

Filed: Dec. 9, 2010

Lead Inventor: Chenyu Zhang, Nanjing University

The invention, the patent application’s abstract states, “provides drugs for treating AIDS, which comprises microvesicles carrying anti-HIV specific siRNA. The … invention also provides a preparation method [for] the drug.”